Latest in Nordisk
Sort by
6 items
-
Novo Nordisk shares pop on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.CNBC - 8h -
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial.The Wall Street Journal - 8h -
Ozempic maker’s stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.MarketWatch - 11h -
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss ...MarketWatch - Jan. 8
